Medicare just made GLP-1 weight-loss drugs a lot more affordable for older Americans. The new Medicare GLP-1 Bridge program offers Wegovy, Zepbound, and Foundayo for just $50/month to eligible Part D enrollees through the end of 2027. But eligibility is narrow, prior authorization is required, and the program's long-term future remains uncertain.
Medicare's new GLP-1 Bridge program officially launched on July 1, offering eligible Part D beneficiaries access to FDA-approved weight-loss drugs — Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo — for just $50 a month. It's the first time Medicare has covered GLP-1s strictly for weight loss, marking a major shift in obesity treatment access for Americans aged 65 and older. The program runs through December 2027, after which its future remains unclear.
Not everyone qualifies, though. Beneficiaries must have a BMI of 35+, or a BMI of 27+ with qualifying conditions like prediabetes or a prior heart attack. Those already getting GLP-1s covered for diabetes, sleep apnea, or fatty liver disease are excluded. Doctors must complete prior authorization, and the $50 copay won't count toward deductibles or out-of-pocket maximums.
Clinicians are raising flags about implementation challenges — from overwhelmed practices and pharmacy inventory shortages to concerns about muscle loss and bone density in older patients on rapid weight-loss regimens.
By the Numbers:
Why it matters: This program could be a lifeline for millions of older Americans who've been priced out of GLP-1 therapy, but its temporary nature and implementation hurdles mean both patients and providers need to plan carefully — and advocate loudly — before the 2027 sunset.
